Table 2.
Posttreatment Ovulation Results in Adolescent Girls With Polycystic Ovary Syndrome Who Were Randomized to Receive an Oral Contraceptive (OC) or Low-Dose Spironolactone + Pioglitazone + Metformin (SPIOMET) for 12 Months, and Were Subsequently Followed for 12 Months Without Treatment. Ovulations Were Assessed Twice Over 12 Weeks, for a Total of 24 Weeks: Between the Study Timepoints of 15 to 18 months (posttreatment months 3-6) and 21 to 24 months (posttreatment months 9-12)
| OC N = 31 | SPIOMET N = 31 | |||||
|---|---|---|---|---|---|---|
| 15-18 mo (12 wk) | 21-24 mo (12 wk) | Total (24 wk) | 15-18 mo (12 wk) | 21-24 mo (12 wk) | Total (24 wk) | |
| Mean number of ovulations ± SEM | 0.8 ± 0.1 | 0.8 ± 0.1 | 1.6 ± 0.2 | 2.3 ± 0.2# | 2.2 ± 0.2# | 4.5 ± 0.3# |
| Median number of ovulations (interquartile range) | 1 (0-1) | 1 (0-1) | 1 (1-3) | 3 (2-3)# | 2 (2-3)# | 5 (3-6)# |
| Normo-ovulatory fraction (%) 5 or 6 ovulations /24 wk | -- | -- | 0 | -- | -- | 62# |
| Oligo-ovulatory fraction (%) 2, 3, or 4 ovulations /24 wk | -- | -- | 47 | -- | -- | 35 |
| An-ovulatory fraction (%) 0 or 1 ovulation /24 wk | -- | -- | 53 | -- | -- | 3# |
# P < 0.0001 between subgroups